Asarfi Hospital vs Prevest Denpro vs Trident Lifeline: Which Stock Should You Track
- October 13, 2026
- Posted by: Kunal Singla
- Category: Market
Asarfi Hospital PE 22.08, mkt cap Rs 393 crore. Prevest Denpro PE 21.01, mkt cap Rs 457 crore. Trident Lifeline PE 20.56, mkt cap Rs 444 crore.
Quick Answer
Asarfi Hospital vs Prevest Denpro vs Trident Lifeline is a side-by-side comparison of three companies from the pharma and healthcare space. On this comparison, Asarfi Hospital carries a market capitalisation of about Rs 393 crore, against Rs 457 crore for Prevest Denpro and Rs 444 crore for Trident Lifeline, with return on equity of 17.47%, 16.42% and 18.97% respectively. Each company’s numbers are presented here without a declared preference, since the right stock depends on an investor’s own criteria.
Asarfi Hospital vs Prevest Denpro vs Trident Lifeline starts with the core numbers most investors compare within the pharma and healthcare segment: market capitalisation, valuation multiples, profitability, dividend yield and the latest quarterly results. Figures below are sourced as of October 2026 and will shift with daily price moves.
All three names sit in the pharma and healthcare bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses. The sections below cover the company profiles, a valuation table, the latest quarter and a five-quarter trend for revenue and net profit.
Click Here – Get Free Investment Predictions
Asarfi Hospital, Prevest Denpro and Trident Lifeline: Company Overview
Asarfi Hospital is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 393 crore, a return on equity of 17.47% and a book value of Rs 51.79 per share. Its quarterly revenue moved from Rs 37.10 crore in June 2025 to Rs 48.10 crore in June 2026, a change of +29.6%.
Prevest Denpro is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 457 crore, a return on equity of 16.42% and a book value of Rs 103.97 per share. Its quarterly revenue moved from Rs 16.94 crore in June 2025 to Rs 20.39 crore in June 2026, a change of +20.4%.
Trident Lifeline is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 444 crore, a return on equity of 18.97% and a book value of Rs 81.39 per share. Its quarterly revenue moved from Rs 24.96 crore in June 2025 to Rs 34.29 crore in June 2026, a change of +37.4%.
Asarfi Hospital vs Prevest Denpro vs Trident Lifeline: Valuation and Profitability Snapshot
| Metric | Asarfi Hospital | Prevest Denpro | Trident Lifeline |
|---|---|---|---|
| Market Cap (approx.) | Rs 393 crore | Rs 457 crore | Rs 444 crore |
| PE Ratio (TTM) | 22.08 | 21.01 | 20.56 |
| PB Ratio | 3.86 | 3.66 | 4.57 |
| Return on Equity (ROE) | 17.47% | 16.42% | 18.97% |
| EPS (TTM, Rs) | 9.05 | 18.10 | 18.07 |
| Dividend Yield | 0.00% | 0.26% | 0.00% |
| Debt to Equity | 0.54 | 0.00 | 0.73 |
| Book Value per Share (Rs) | 51.79 | 103.97 | 81.39 |
Check the Univest Screener for Live Data
On valuation, Asarfi Hospital trades at a PE of 22.08 and a PB of 3.86, Prevest Denpro at a PE of 21.01 and a PB of 3.66, while Trident Lifeline trades at a PE of 20.56 and a PB of 4.57. On return on equity, the three post 17.47%, 16.42% and 18.97% respectively, and on dividend yield they stand at 0.00%, 0.26% and 0.00%. Prevest Denpro has the highest market capitalisation of the three at Rs 457 crore, while Asarfi Hospital has the lowest at Rs 393 crore. Asarfi Hospital has the highest PE ratio of the three at 22.08, while Trident Lifeline has the lowest at 20.56. Trident Lifeline has the highest return on equity of the three at 18.97%, while Prevest Denpro has the lowest at 16.42%. Trident Lifeline has the highest debt to equity ratio of the three at 0.73, while Prevest Denpro has the lowest at 0.00. Debt to equity is 0.54, 0.00 and 0.73 for the three respectively.
Asarfi Hospital vs Prevest Denpro vs Trident Lifeline: Latest Quarterly Results
| Company | Latest Quarter Revenue | Latest Quarter Net Profit | YoY Change (Revenue) | QoQ Change (Revenue) | YoY Change (Net Profit) |
|---|---|---|---|---|---|
| Asarfi Hospital | Rs 48.10 crore | Rs 4.27 crore | +29.6% | +4.8% | +36.9% |
| Prevest Denpro | Rs 20.39 crore | Rs 5.64 crore | +20.4% | +0.2% | +27.9% |
| Trident Lifeline | Rs 34.29 crore | Rs 5.07 crore | +37.4% | -33.5% | +82.4% |
Quarterly figures above are the most recent reported quarter for each company (Q1 FY27, quarter ended June 2026), compared with the year-ago and preceding quarter. A percentage change in net profit is shown as NA where the comparison quarter was a loss or the latest quarter is a loss, since the percentage is not meaningful in that case.
Asarfi Hospital vs Prevest Denpro vs Trident Lifeline: Five-Quarter Revenue and Net Profit Trend
The five-quarter view below shows how revenue and net profit moved from June 2025 to June 2026 for each company in Asarfi Hospital vs Prevest Denpro vs Trident Lifeline, which helps separate a one-quarter move from a steadier pattern.
Quarterly revenue (Rs crore)
| Quarter | Asarfi Hospital | Prevest Denpro | Trident Lifeline |
|---|---|---|---|
| June 2025 | Rs 37.10 crore | Rs 16.94 crore | Rs 24.96 crore |
| September 2025 | Rs 45.65 crore | Rs 19.83 crore | Rs 33.01 crore |
| December 2025 | Rs 47.58 crore | Rs 19.61 crore | Rs 30.34 crore |
| March 2026 | Rs 45.88 crore | Rs 20.35 crore | Rs 51.57 crore |
| June 2026 | Rs 48.10 crore | Rs 20.39 crore | Rs 34.29 crore |
Quarterly net profit (Rs crore)
| Quarter | Asarfi Hospital | Prevest Denpro | Trident Lifeline |
|---|---|---|---|
| June 2025 | Rs 3.12 crore | Rs 4.41 crore | Rs 2.78 crore |
| September 2025 | Rs 4.20 crore | Rs 5.54 crore | Rs 5.09 crore |
| December 2025 | Rs 5.42 crore | Rs 4.72 crore | Rs 4.65 crore |
| March 2026 | Rs 3.92 crore | Rs 5.82 crore | Rs 6.80 crore |
| June 2026 | Rs 4.27 crore | Rs 5.64 crore | Rs 5.07 crore |
Asarfi Hospital reported revenue of Rs 37.10 crore in June 2025 and Rs 48.10 crore in June 2026, a change of +29.6% across the period. Its highest quarterly revenue in this window was Rs 48.10 crore in June 2026. Net profit stood at Rs 4.27 crore in June 2026, which is a net profit margin of 8.88%.
Prevest Denpro reported revenue of Rs 16.94 crore in June 2025 and Rs 20.39 crore in June 2026, a change of +20.4% across the period. Its highest quarterly revenue in this window was Rs 20.39 crore in June 2026. Net profit stood at Rs 5.64 crore in June 2026, which is a net profit margin of 27.66%.
Trident Lifeline reported revenue of Rs 24.96 crore in June 2025 and Rs 34.29 crore in June 2026, a change of +37.4% across the period. Its highest quarterly revenue in this window was Rs 51.57 crore in March 2026. Net profit stood at Rs 5.07 crore in June 2026, which is a net profit margin of 14.79%.
Download the Univest iOS App or Univest Android App to track Asarfi Hospital, Prevest Denpro and Trident Lifeline live prices.
What Should Investors Look at Beyond These Numbers?
Beyond the metrics above, investors comparing these three pharma and healthcare names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and factors specific to the segment such as patient volumes, regulatory approvals, product mix and the small revenue base that makes quarterly results swing. A single-quarter snapshot can shift quickly, and smaller companies in particular can show wide swings from one quarter to the next.
It also helps to read the latest quarterly filings and investor presentations of Asarfi Hospital, Prevest Denpro and Trident Lifeline directly, since the figures here come from standardised data and do not capture company-specific context such as one-time items, order timing or promoter actions.
Conclusion
Asarfi Hospital vs Prevest Denpro vs Trident Lifeline highlights how differently three companies in the same pharma and healthcare segment can look across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.
Disclaimer: Data and figures in this article are sourced from publicly available information as of October 2026 and may not reflect real-time prices. Please verify all data independently before making any investment decision. This comparison does not recommend or endorse any single stock over another; investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Asarfi Hospital vs Prevest Denpro vs Trident Lifeline
What is the market cap difference between Asarfi Hospital, Prevest Denpro and Trident Lifeline?
Ans. As of October 2026, Asarfi Hospital has a market cap of approximately Rs 393 crore, Prevest Denpro is at approximately Rs 457 crore, and Trident Lifeline is at approximately Rs 444 crore.
What are the PE and PB ratios of Asarfi Hospital, Prevest Denpro and Trident Lifeline?
Ans. As of October 2026, the PE ratios stand at 22.08, 21.01 and 20.56 respectively, and the price to book ratios stand at 3.86, 3.66 and 4.57 respectively.
Which of the three has the highest ROE?
Ans. Asarfi Hospital, Prevest Denpro and Trident Lifeline post ROE of 17.47%, 16.42% and 18.97% respectively as of October 2026. Trident Lifeline has the highest return on equity of the three at 18.97%, while Prevest Denpro has the lowest at 16.42%.
Which of these three stocks pays the highest dividend yield?
Ans. Asarfi Hospital, Prevest Denpro and Trident Lifeline carry dividend yields of 0.00%, 0.26% and 0.00% respectively.
What is the debt to equity ratio for Asarfi Hospital, Prevest Denpro and Trident Lifeline?
Ans. Asarfi Hospital carries a debt to equity of 0.54, Prevest Denpro of 0.00, and Trident Lifeline of 0.73.
What were the latest quarterly revenue and net profit of Asarfi Hospital, Prevest Denpro and Trident Lifeline?
Ans. For Q1 FY27 (quarter ended June 2026), Asarfi Hospital reported revenue of Rs 48.10 crore and net profit of Rs 4.27 crore, Prevest Denpro reported revenue of Rs 20.39 crore and net profit of Rs 5.64 crore, and Trident Lifeline reported revenue of Rs 34.29 crore and net profit of Rs 5.07 crore.
Does this comparison recommend one of Asarfi Hospital, Prevest Denpro and Trident Lifeline?
Ans. This comparison does not declare one stock ahead of another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor’s own criteria and research.
